Therapeutic Asset Ratings

766 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
68ga-my Breast Cancer	Peking University Cancer Hospital & Institute	N/A	D (26)
68ga-nota-nectin-4 antibody fragment Breast Cancer	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	N/A	D (26)
[68ga]psma Prostate Cancer	University Hospitals Cleveland Medical Center		D (26)
99m tc-tm Breast Cancer	Johns Hopkins University		D (26)
Lutetium-Psma Prostate Cancer	Medical University of Vienna		D (26)
Cu-Nu101 Prostate Cancer	Hoag Memorial Hospital Presbyterian	P2	NR (0)
Terbium 161- Psma I&T Prostate Cancer	Ankara University	P2	NR (0)
212pb-dotam Colorectal Cancer	Hoffmann-La Roche	P1	NR (0)
68ga-gp-01 Solid Tumor Malignancies	GrandPharma (China) Co., Ltd.	P1	NR (0)
Lutetium [177Lu]-Fap-75 Neoplasm	Fudan University	P1	NR (0)
161tb-lnc1011 Prostate Cancer	Peking Union Medical College Hospital	Early P1	NR (0)
177lu-fc516 Prostate Cancer	FindCure Biosciences (ZhongShan) Co., Ltd.	Early P1	NR (0)
[177lu]lu-psma-137 Prostate Cancer	Peking University First Hospital	Early P1	NR (0)
68ga-sfb6-zn01 Neoplasm	Zhongnan Hospital	Early P1	NR (0)
gpa33-cc;177lu-smartd2 Colorectal Cancer	SmartNuclide Biopharma	Early P1	NR (0)
18f-g1 Cancer	Peking University First Hospital		NR (0)

Showing 751 to 766 of 766 assets

PreviousPage 31 of 31Next